These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
294 related articles for article (PubMed ID: 27680764)
21. Successful treatment of extensively drug-resistant Acinetobacter baumannii peritoneal dialysis peritonitis with intraperitoneal polymyxin B and ampicillin-sulbactam. Fitzpatrick MA; Esterly JS; Postelnick MJ; Sutton SH Ann Pharmacother; 2012; 46(7-8):e17. PubMed ID: 22811349 [TBL] [Abstract][Full Text] [Related]
22. Treatment of peritoneal dialysis-related peritonitis with ciprofloxacin monotherapy: clinical outcomes and bacterial susceptibility over two decades. Fontán MP; Cambre HD; Rodríguez-Carmona A; Muñiz AL; Falcón TG Perit Dial Int; 2009; 29(3):310-8. PubMed ID: 19458304 [TBL] [Abstract][Full Text] [Related]
23. Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU. Sheng WH; Wang JT; Li SY; Lin YC; Cheng A; Chen YC; Chang SC Diagn Microbiol Infect Dis; 2011 Jul; 70(3):380-6. PubMed ID: 21558048 [TBL] [Abstract][Full Text] [Related]
24. [Analysis of clinical characteristics and antimicrobial resistance of carbapenem-resistant Acinetobacter baumannii infections in children]. Zhang TQ; Dong L; Wang ZY; Li HY Zhonghua Er Ke Za Zhi; 2011 Jul; 49(7):545-9. PubMed ID: 22088187 [TBL] [Abstract][Full Text] [Related]
25. [Mechanism of drug resistance of carbapenems-resistant Acinetobacter baumannii and the application of a combination of drugs in vitro]. Zhao C; Xie W; Zhang W; Ye Z; Wu H Zhonghua Shao Shang Za Zhi; 2014 Apr; 30(2):166-70. PubMed ID: 24989663 [TBL] [Abstract][Full Text] [Related]
26. Effects of a Statewide Protocol for the Management of Peritoneal Dialysis-Related Peritonitis on Microbial Profiles and Antimicrobial Susceptibilities: A Retrospective Five-Year Review. McGuire AL; Carson CF; Inglis TJ; Chakera A Perit Dial Int; 2015 Dec; 35(7):722-8. PubMed ID: 26152579 [TBL] [Abstract][Full Text] [Related]
27. Long-Term Exit-Site Gentamicin Prophylaxis and Gentamicin Resistance in a Peritoneal Dialysis Program. Chen SS; Sheth H; Piraino B; Bender F Perit Dial Int; 2016; 36(4):387-9. PubMed ID: 26634567 [TBL] [Abstract][Full Text] [Related]
28. Risk of Peritoneal Dialysis-Related Peritonitis in a Multi-Racial Asian Population. Ong LM; Ch'ng CC; Wee HC; Supramaniam P; Zainal H; Goh BL; Bavanandan S; Mushahar L; Hooi LS; Ahmad G Perit Dial Int; 2017 1-2; 37(1):35-43. PubMed ID: 27147287 [TBL] [Abstract][Full Text] [Related]
29. Clinical characteristics and outcome of Acinetobacter infections in CAPD patients. Lye WC; Lee EJ; Leong SO; Kumarasinghe G Perit Dial Int; 1994; 14(2):174-7. PubMed ID: 8043675 [No Abstract] [Full Text] [Related]
30. Microbiology of peritoneal dialysis-related infection and factors of refractory peritoneal dialysis related peritonitis: A ten-year single-center study in Taiwan. Wang HH; Huang CH; Kuo MC; Lin SY; Hsu CH; Lee CY; Chiu YW; Chen YH; Lu PL J Microbiol Immunol Infect; 2019 Oct; 52(5):752-759. PubMed ID: 30665844 [TBL] [Abstract][Full Text] [Related]
31. Characteristics and outcomes of fungal peritonitis in a modern North American cohort. Nadeau-Fredette AC; Bargman JM Perit Dial Int; 2015; 35(1):78-84. PubMed ID: 24497586 [TBL] [Abstract][Full Text] [Related]
33. [Susceptibility pattern of Acinetobacter baumannii clinical isolates in Madrid vs. Hong Kong]. García-Peñuela E; Aznar E; Alarcón T; López-Brea M Rev Esp Quimioter; 2006 Mar; 19(1):45-50. PubMed ID: 16688291 [TBL] [Abstract][Full Text] [Related]
34. Fungal peritonitis in peritoneal dialysis: 5-year review from a North China center. Hu S; Tong R; Bo Y; Ming P; Yang H Infection; 2019 Feb; 47(1):35-43. PubMed ID: 30145773 [TBL] [Abstract][Full Text] [Related]
36. Risk factors for peritoneal dialysis-associated peritonitis: the role of oral active vitamin d. Rudnicki M; Kerschbaum J; Hausdorfer J; Mayer G; König P Perit Dial Int; 2010; 30(5):541-8. PubMed ID: 20228174 [TBL] [Abstract][Full Text] [Related]
37. In vitro activity of cefepime combined with sulbactam against clinical isolates of carbapenem-resistant Acinetobacter spp. Tong W; Wang R; Chai D; Li Z; Pei F Int J Antimicrob Agents; 2006 Nov; 28(5):454-6. PubMed ID: 16987639 [TBL] [Abstract][Full Text] [Related]
38. The Trio Trial - A Randomized Controlled Clinical Trial Evaluating the Effect of a Biocompatible Peritoneal Dialysis Solution on Residual Renal Function. Sikaneta T; Wu G; Abdolell M; Ng A; Mahdavi S; Svendrovski A; Tu T; Mercer T; Tong M; Oreopoulos D; Tam P Perit Dial Int; 2016 9-10; 36(5):526-32. PubMed ID: 27282852 [TBL] [Abstract][Full Text] [Related]
39. Phenotypic characterization and colistin susceptibilities of carbapenem-resistant of Pseudomonas aeruginosa and Acinetobacter spp. Mohanty S; Maurya V; Gaind R; Deb M J Infect Dev Ctries; 2013 Nov; 7(11):880-7. PubMed ID: 24240048 [TBL] [Abstract][Full Text] [Related]
40. Stable carbapenem susceptibility rates among multidrug-resistant Acinetobacter spp. strains in a setting of high prevalence of carbapenem-resistant Pseudomonas aeruginosa. Zavascki AP; Soares FC; Superti SV; Silbert S; Silva FM; Barth AL Int J Antimicrob Agents; 2007 Aug; 30(2):187-9. PubMed ID: 17452093 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]